Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 13/09/2024 pm IST			5-day change	1st Jan Change
1,800.00 ^DKK	+1.18%		-3.23%	-16.47%

07:01am	Genmab Reports 'Encouraging Response Rate' from Investigational Ovarian Cancer Treatment Trial	MT
15/09	Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha-Targeted, Topo1 Antibody-Drug Conjugate	CI

Genmab A/S Announces DARZALEX Sales Results for the Second Quarter of 2024

July 17, 2024 at 07:31 pm IST

Genmab A/S announced DARZALEX sales results for the second quarter of 2024. For the quarter, the company reported net sales of DARZALEX were USD 2,878 million. Net trade sales were USD 1,641 million in the U.S. and USD 1,237 million in the rest of the world.

Latest news about Genmab A/S

Genmab Reports 'Encouraging Response Rate' from Investigational Ovarian Cancer Treatment Trial	10:31am	MT
Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha-Targeted, Topo1 Antibody-Drug Conjugate	15/09	CI
Truist Lowers Price Target on Genmab to $50 From $53, Maintains Buy Rating	09/09	MT
Transcript : Genmab A/S Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 01:05 PM	04/09
Morgan Stanley Upgrades Genmab to Equalweight, Price Target is $31	04/09	MT
HOOKIPA Pharma Names Julie O'Neill Nonexecutive Chair	30/08	MT
European Equities Close Lower in Tuesday Trading; Euro Area, EU Inflation Rises Slightly	20/08	MT
Global markets live: Rio Tinto, GSK, Palo Alto, GM, Lowe's...	20/08
Genmab Wins Conditional EU Approval for Follicular Lymphoma Antibody	20/08	MT
AbbVie, Genmab Lymphoma Treatment Gets European Commission Marketing Authorization	20/08	DJ
Genmab, AbbVie Get Conditional European Commission Approval for Lymphoma Treatment	20/08	MT
Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	19/08	CI
Genmab Names First Chief Technology, Chief Commercial Officers; COO to Exit	16/08	MT
Genmab COO Anthony Mancini Departs; Firm Names New CTO, CCO	16/08	MT
Genmab Operations Chief Anthony Mancini Departing	16/08	MT
Genmab A/S Announces Executive Changes	16/08	CI
AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly? (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process	15/08	CI
GENMAB : Better-than-expected Q2 + guidance upgrade	09/08
Genmab: updates 2024 financial forecasts	09/08	CF
Genmab's Interim Q2 Earnings, Revenue Climb; Increases 2024 Revenue Guidance	09/08	MT
Genmab Posts Higher H1 Profit; Revenue Advances	09/08	MT
Transcript : Genmab A/S, H1 2024 Earnings Call, Aug 08, 2024	08/08
Genmab A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08/08	CI
Global markets live: Amazon, Intel, Boeing, Robinhood, KKR, Zillow...	08/08
Genmab A/S Revises Earnings Guidance for the Year 2024	08/08	CI

Chart Genmab A/S

Duration

Period

More charts

Company Profile

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.

Employees

2,526

Sector

Biotechnology & Medical Research

Calendar

06/11/2024 - Q3 2024 Earnings Release

More about the company